Učitavanje...
Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study
PURPOSE: In the multinational, randomized, double-blind, Phase 3 B2305 study of patients with Cushing’s disease (CD; ClinicalTrials.gov identifier NCT00434148), pasireotide substantially decreased urinary-free cortisol (UFC) levels, decreased mean corticotroph tumor volume, and improved clinical sig...
Spremljeno u:
| Izdano u: | Pituitary |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer US
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7181422/ https://ncbi.nlm.nih.gov/pubmed/31875276 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11102-019-01021-2 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|